Industries > Pharma > Global Smoking Cessation Drugs Market Forecast 2017-2027
Global Smoking Cessation Drugs Market Forecast 2017-2027
NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs
The global smoking cessation drugs market is expected to grow at a CAGR of 14.9% in the first half of the forecast period. In 2016, the non-nicotine pharmacotherapy submarket held 56.2% of the global smoking cessation drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 280-page report you will receive 175 tables and 150 figures– all unavailable elsewhere.
The 280-page report provides clear detailed insight into the global smoking cessation drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Smoking Cessation Drugs market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the global smoking cessation drugs market by type of therapy:
– NRT
– Non-Nicotine Pharmacotherapy
• This report also breaks down the revenue forecast for the global smoking cessation drugs market by prescription vs OTC:
– Prescription drugs
– OTC
• This report provides individual revenue forecasts to 2027 for these regions:
– North America
– Europe
– Asia-Pacific
– RoW
Each region is further segmented by type of therapy.
• This report provides the following qualitative analysis:
– Epidemiology by geography, available treatment options, along with humanistic and economic burden
– A SWOT Analysis
– Pipeline molecules which are under development for the treatment of smoking cessation and detailed analysis on promising drug candidates
– Pricing and reimbursement overview of the smoking cessation drugs market.
– Leading companies that are the major players in the global smoking cessation drugs industry, including Pfizer, GlaxoSmithKline and Johnson & Johnson.
Visiongain’s study is intended for anyone requiring commercial analyses for the global smoking cessation drugs market. You find data, trends and predictions.
Buy our report today Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated visiongain Reports
1.8 About visiongain
2. Introduction to Smoking Cessation
2.1 What is Smoking?
2.1.1 Types of Tobacco Smoking
2.2 What are the various types of nicotine delivery systems?
2.3 Epidemiology of Smoking
2.3.1 Historical and Forecasted Prevalence of Current Tobacco Smoking in WHO Regions
2.3.2 Prevalence of Tobacco Smoking in the Major Markets
2.3.2.1 US
2.3.2.2 Australia
2.3.2.3 New Zealand
2.3.2.4 Italy
2.3.2.5 Germany
2.3.2.6 Spain
2.3.2.7 France
2.3.2.8 UK
2.4 Humanistic and Economic Burden
2.4.1 Mortality
2.4.2 Years Lost due to Disability (YLD)
2.4.3 Labour-years Lost (LYL)
2.4.4 Economic Impact
2.5 Smoking: Prevention and Treatment
2.5.1 Prevention
2.5.2 Treatment
3. Introduction to the Global Smoking Cessation Drugs Market
3.1 Market Definition and Scope
3.2 Global Smoking Cessation Drugs Market 2016
3.2.1 Global Smoking Cessation Drugs Market Forecast 2017-2027
3.3 Global Market Segmentation by Drug Class
3.3.1 Market Forecast by Drug Class, 2016-2027
3.4 Global Market Segmentation by Region
3.4.1 Market Forecast by Region, 2016-2027
3.4.1.1 North America
3.4.1.2 Europe
3.4.1.3 Asia-Pacific (Japan, Australia, and New Zealand)
3.4.1.4 RoW (Emerging Markets)
3.5 Global Market Segmentation by Country
3.6 Regional Market Segmentation by Drug Class, 2016-2027
3.6.1 North America
3.6.2 Europe
3.6.3 Asia-Pacific (Japan, Australia, and New Zealand)
3.6.4 Rest of the World (Emerging Markets)
3.7 Overall Global Smoking Cessation Drugs Market Drivers, Restraints and Trends
4. Research and Development for Treating Smoking Cessation
4.1 Novel Mechanism of Action of Pipeline Drugs
4.2 Active Pipeline Molecules
4.2.1 X-22
4.2.2 CQSS 2 (Chrono Quit Smoking Solution 2) System
4.2.3 CERC-501
4.2.4 SEL-070 (SELA-070)
4.2.5 EMB-001
4.2.6 CVSI-007
4.3 Discontinued Molecules
4.3.1 NicVax
4.3.2 SSR591813 (Dianicline)
4.3.3 SR141716 (Rimonabant)
4.3.4 TA-NIC
4.3.5 Nic-002
4.3.6 MK-0364 (Taranabant)
4.3.7 SR147778 (Surinabant)
4.3.8 APD356 (lorcaserin)
4.3.9 GW468816
4.3.10 EVP-6124
4.3.11 GSK598809
4.3.12 PF-05402536 (NIC7-001) and PF-06413367 (NIC7-003)
5. Pricing and Reimbursement Overview
5.1 Australia
5.2 New Zealand
5.3 Germany
5.4 France
5.5 Italy
5.6 Spain
5.7 UK
5.8 US
6. Smoking Cessation Therapies and NRT Market Overview, by Geography
6.1 US
6.2 UK
6.3 Spain
6.4 France
6.5 Australia
6.6 New Zealand
6.7 Italy
6.8 Germany
7. Qualitative Analysis of the Global Smoking Cessation Drugs Market
7.1 SWOT Analysis, 2016
7.2 Leading Companies in Global Smoking Cessation Drugs Market, 2016
7.2.1 Pfizer
7.2.2 GSK
7.2.3 J&J
8. Conclusions
Appendices
Glossary
Associated visiongain Reports
Visiongain Report Sales Order Form
About visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Age-standardized Prevalence of Tobacco Smoking in People Aged 15 Years and More, by WHO Region, 2015
Table 2.2 WHO Definitions for Smoking Status
Table 2.3 Prevalence (%) of Current Tobacco Smoking in WHO Regions by Gender, 2010 and 2025
Table 2.4 List of Countries with >= 25% of Current Tobacco Smoking, in People Aged 15 Years and Above, 2015
Table 2.5 List of Countries with >= 25% of Daily Tobacco Smoking, in People Aged 15 Years and Above, 2015
Table 2.6 Crude Prevalence (%)of Current Tobacco Smoking in Key Geographies by Gender, 2010 and 2025
Table 2.7 Crude Prevalence (%) of Daily Tobacco Smoking in Key Geographies by Gender, 2010 and 2025
Table 2.8 Crude Prevalence (%) of Current Cigarette Smoking in Key Geographies by Gender, 2010 and 2025
Table 2.9 Crude Prevalence (%) of Daily Cigarette Smoking in Key Geographies by Gender, 2010 and 2025
Table 2.10 Prevalence (%) of Age-standardized Tobacco Smoking in People Aged 15 Years and More, 2015
Table 2.11 Key Tobacco and Smoking Related Surveys Conducted and/or Supported by the Office on Smoking and Health, US
Table 2.12 Prevalence (%)of Current Cigarette Smoking Among High School Students and Adults in the US, 1965–2014
Table 2.13 Prevalence (%) of Using Tobacco Products in Middle and High School Students by Product in the US, 2016
Table 2.14 Prevalence (%) of Using Tobacco Products in Middle and High School Students by Product in the US, 2015
Table 2.15 Percent of Students Who Report Smoking Cigarettes Daily in the US, by grade, 1976-2015
Table 2.16 Percent of Students who Reported Using Smokeless Tobacco in the US in the Last 30 Days, by grade, 1993-2015
Table 2.17 Prevalence of Any Tobacco Use of Any Tobacco Product among Adults Aged 18 Years and Over, by Gender and Age Group, US, 2009-2014
Table 2.18 Prevalence of Current Cigarette Smoking among Adults Aged 18 Years and Over, by Gender and Year, US, 1991-2015
Table 2.19 Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over, by Age Group and Year, US, 1965-2014
Table 2.20 Prevalence of Current Cigarette Smoking among Females aged 18 Years and Over, by Age Group and Year, US, 1965-2014
Table 2.21 Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Age Group, Gender, and Smoking Status, US, 2013-2015
Table 2.22 Prevalence (%) of Daily Tobacco Smoking by Gender, US, 2010, 2025 and 2030
Table 2.23 Prevalence (%) of Current Tobacco Smoking by Gender, US, 2010, 2025 and 2030
Table 2.24 Tobacco Smoking among People aged 14 Years and Over, by Smoking Status, Australia, 1991-2015 (%)
Table 2.25 Distribution of Tobacco Smoking Status among People aged 12 Years and Over, by Age Group and Gender, Australia, 2016
Table 2.26 Distribution of Tobacco Smoking Status among People aged 12 Years and Over, by Age Group and Gender, Australia, 2016
Table 2.27 Number of Smokers (in thousands), by Smoking Status, Age Group and Gender, Australia, 2014-2015
Table 2.28 Five-year Prevalence (%) of Current Tobacco Smoking in Australia, by Gender, 2000-2030
Table 2.29 Prevalence (%) of Current Tobacco Smoking in Australia, by Age, 2000-2030
Table 2.30 Prevalence (%) of Current Tobacco Smoking in Australia, by Age and Gender, 2000-2030
Table 2.31 Five-year Prevalence (%) of Daily Tobacco Smoking in Australia, by Gender, 2000-2030
Table 2.32 Definitions for Smoking Status Used in New Zealand Health Survey
Table 2.33 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2006-2016
Table 2.34 Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Table 2.35 Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group and Gender, 2015/2016
Table 2.36 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2006-2016
Table 2.37 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Table 2.38 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Age Group and Gender, 2015/2016
Table 2.39 Prevalence (%) of Current Tobacco Smoking in New Zealand, 1983-2015
Year
Table 2.40 Five-year Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2000-2030
Table 2.41 Five-year Prevalence (%) of Current Tobacco Smoking in New Zealand, by Gender, 2000-2030
Table 2.42 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2016
Table 2.43 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Gender, Italy, 2007-2016
Table 2.44 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Table 2.45 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Table 2.46 Prevalence (in %) of Smoking in Males Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Table 2.47 Prevalence (in %) of Smoking in Females Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Table 2.48 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age , Italy, 2007-2016
Table 2.49 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status and Age, Italy, 2001-2003 and 2005-2016
Table 2.50 Five-year Prevalence (%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
Table 2.51 Prevalence (%) of Current Tobacco Smoking in Italy, by Age, 2000-2030
Table 2.52 Prevalence (%) of Current Tobacco Smoking in Italy, by Age and Gender, 2000-2030
Table 2.53 Five-year Prevalence (%) of Daily Tobacco Smoking in Italy, by Gender, 2000-2030
Table 2.55 Definitions for Smoking Status used by Federal Health Reporting System
Table 2.56 Surveys Used to Determine Smoking Behavior by Federal Health Reporting System, Germany
Table 2.57 Prevalence (%) of Smoking in People aged 18 Years and Above, by Gender, Germany, 2009-2014/2015
Table 2.58 Prevalence (%) of Smoking in People aged 18 Years and Above, by Age and Gender, Germany, 2009-2014/2015
Table 2.59 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
Table 2.60 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
Table 2.61 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
Table 2.62 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
Table 2.63 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
Table 2.64 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
Table 2.65 Prevalence (%) of Smoking in People Aged 15 Years and Above, by Smoking Status and Gender, Germany, 1992-2013
Table 2.66 Prevalence (%) of Smoking in People Aged 15 Years and Above, by Age and Gender, Germany, 1992-2013
Table 2.67 Five-year Prevalence (%) of Current Tobacco Smoking in Germany, by Gender, 2000-2030
Table 2.68 Prevalence(%) of Current Tobacco Smoking in Germany, by Age, 2000-2030
Table 2.69 Prevalence(%) of Current Tobacco Smoking in Germany, by Age and Gender, 2000-2030
Table 2.70 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, by Gender, 2000-2030
Table 2.71 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2014
Table 2.72 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2014
Table 2.73 Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender, Age, and Smoking Status, in Spain, 2014
Table 2.74 Number of Current Tobacco Smokers Aged 15 Years and Above – Daily and Occasional (in thousands), by Gender, in Spain, 2011-2012
Table 2.75 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2011-2012
Table 2.76 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2011-2012
Table 2.77 Prevalence (%) of Tobacco Smoking, by Gender, Age, and Smoking Status in People Aged 15 Years and Above, in Spain, 2011-2012
Table 2.78 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
Table 2.79 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
Table 2.80 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
Table 2.81 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
Table 2.82 Five-year Prevalence (%) of Current Tobacco Smoking in Spain, by Gender, 2000-2030
Table 2.83 Prevalence (%) of Current Tobacco Smoking in Spain, by Age, 2000-2030
Table 2.84 Prevalence (%) of Current Tobacco Smoking in Spain, by Age and Gender, 2000-2030
Table 2.85 Five-year Prevalence (%) of Daily Tobacco Smoking in Spain, by Gender, 2000-2030
Table 2.86 Distribution of Smoking Status (in %), in France, 2010 and 2014
Table 2.87 Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Table 2.88 Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Table 2.89 Five-year Prevalence (%) of Current Tobacco Smoking in France, by Gender, 2000-2030
Table 2.90 Prevalence (%) of Current Tobacco Smoking in France, by Age, 2000-2030
Table 2.91 Prevalence (%) of Current Tobacco Smoking in France, by Age and Gender, 2000-2030
Table 2.92 Five-year Prevalence (%) of Daily Tobacco Smoking in France, by Gender, 2000-2030
Table 2.93 Prevalence (%) of Current Tobacco Smoking in People Aged 18 Years and Above, in the UK, 2010-2016
Table 2.94 Prevalence (%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age, in the UK, 2010-2016
Table 2.95 Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Gender, in the UK, 2010-2015
Table 2.96 Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.97 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.98 Prevalence (%) of Current Tobacco Smoking in Females Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.99 Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Gender, in the UK, 2010-2015
Table 2.100 Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.101 Prevalence (%) of Daily Tobacco Smoking in Females Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.102 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age, in the UK, 2010-2015
Table 2.103 Prevalence (%) of Tobacco Smoking in, by Gender and Smoking Status, in the UK, 2010, 2025, and 2030
Table 2.104 Number of Smoking-related Deaths in the WHO Regions, All Ages, 2010
Table 2.105 Smoking-attributable Burden of Disease and LYL Among Adults aged 30–69 years, 2012
Table 2.106 Smoking-attributable Burden of Disease, by Geography, 2012
Table 2.107 Economic Cost of Smoking-attributable Diseases, 2012
Table 2.108 Economic Cost of Smoking-attributable Diseases, Adjusted for 2016 PPP
Table 3.1 Global Smoking Cessation Drugs Market by Segmentation, 2016
Table 3.2 Global Smoking Cessation Drugs Market Forecast 2017-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.3 Global Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.4 Global Smoking Cessation Drugs Market by Region, 2016
Table 3.5 Global Smoking Cessation Drugs Market Forecast by Region 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.6 Global Smoking Cessation Drugs Market by Country, 2016
Table 3.7 North American Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.8 European Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.9 APAC Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 3.10 RoW Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.1 Active Pipeline Molecules for Smoking Cessation, 2017
Table 4.2 Discontinued Pipeline Molecules for Smoking Cessation, 2017
Table 5.1 Status of Smoking Cessation Reimbursement in Australia, as of December 2016
Table 5.2 Status of Smoking Cessation Reimbursement in New Zealand, as of December 2016
Table 5.3 Status of Smoking Cessation Reimbursement in Germany, as of December 2016
Table 5.4 Status of Smoking Cessation Reimbursement in France, as of December 2016
Table 5.5 Status of Smoking Cessation Reimbursement in Italy, as of December 2016
Table 5.6 Status of Smoking Cessation Reimbursement in Spain, as of December 2016
Table 5.7 Status of Smoking Cessation Reimbursement in the UK, as of December 2016
Table 5.8 Status of Smoking Cessation Reimbursement in the US, as of December 2016
Table 6.1 Type of Smoking Cessation Therapies Approved in the US, 2017
Table 6.2 List of Smoking Cessation Drugs Approved in the US, 2017
Table 6.3 List of Smoking Cessation Drugs with Discontinued/Tentative Approval Marketing Status in the US, 2017
Table 6.4 NRT Market in the US
Table 6.5 NRT Market Leaders for Traditional Product Categories in the US, 2016
Table 6.6 Nicotine Gums Market in the US
Table 6.7 Nicotine Lozenges Market in the US
Table 6.8 Nicotine Patch Market in the US
Table 6.9 Non-Nicotine Smoking Cessation Pharmacotherapy Market in the US
Table 6.10 Usage of Any Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016
Table 6.11 Usage of Only One Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016
Table 6.12 Type of Smoking Cessation Therapies Approved in the UK, 2017
Table 6.13 List of Smoking Cessation Drugs Approved in the UK, 2017
Table 6.14 List of Smoking Cessation Drugs with Discontinued Marketing Status in the UK, 2017
Table 6.15 NRT Market in the UK
Table 6.16 Nicotine Gums Market in the UK
Table 6.17 Nicotine Lozenges Market in the UK
Table 6.18 Nicotine Patches Market in the UK
Table 6.19 Non-Nicotine Smoking Cessation Pharmacotherapy Market in the UK
Table 6.20 Number of Prescriptions (in thousands) of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
Table 6.21 Net Ingredient Cost of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
Table 6.22 Type of Smoking Cessation Therapies Approved in Spain, 2017
Table 6.23 List of Smoking Cessation Drugs Approved in Spain, 2017
Table 6.24 List of Smoking Cessation Drugs with Discontinued Marketing Status in Spain, 2017
Table 6.25 NRT Market in Spain
Table 6.26 Type of Smoking Cessation Therapies Approved in France, 2017
Table 6.27 List of Smoking Cessation Drugs Approved in France, 2017
Table 6.28 NRT Market in France, 2017
Table 6.29 Type of Smoking Cessation Therapies Approved in Australia, 2017
Table 6.30 List of Smoking Cessation Drugs Approved in Australia, 2017
Table 6.31 NRT Market in Australia
Table 6.32 Type of Smoking Cessation Therapies Approved in New Zealand, 2017
Table 6.33 List of Smoking Cessation Drugs Approved in New Zealand, 2017
Table 6.34 List of Smoking Cessation Drugs with Lapsed Approval in New Zealand, 2017
Table 6.35 List of Smoking Cessation Drugs with Status ‘Not Available’ in New Zealand, 2017
Table 6.36 NRT Market in New Zealand
Table 6.37 Type of Smoking Cessation Therapies Approved in Italy, 2017
Table 6.38 List of Smoking Cessation Drugs Approved in Italy, 2017
Table 6.39 List of Smoking Cessation Drugs with status ‘Revoked’ in Italy, 2017
Table 6.40 NRT Market in Italy
Table 6.41 NRT Market in Germany
Table 7.1 Global Smoking Cessation Market Leaders, 2016
Table 7.2 Sales (in US$ Million) of Chantix/Champix
Table 7.3 Chantix: Exclusivity and Patent Expiry Status in the US
Table 7.4 Sales of Perrigo’s Smoking Cessation Products
Table 8.1 Age-standardized Prevalence of Tobacco Smoking in People Aged 15 Years and More, by WHO Region, 2015
Table 8.2 Prevalence (%) of Current Tobacco Smoking in WHO Regions by Gender, 2010 and 2025
List of Figures
Figure 2.1 Types of Nicotine Delivery Systems
Figure 2.2 Prevalence (%) of Current Tobacco Smoking in WHO Regions, 2010 and 2025
Figure 2.3 Trend of Current Cigarette Smoking Among High School Students and Adults in the US, 1965–2014
Figure 2.4 Trend of Current Cigarette Smoking Among High School Students in the US, 2011-2016
Figure 2.5 Trend of Current Cigarette Smoking Among Middle School Students in the US, 2011-2016
Figure 2.6 Trend of Daily Cigarette Smoking in the US, by Grade, 1976-2015
Figure 2.7 Trend of Students who Reported Using Smokeless Tobacco in the US in the Last 30 Days, by Grade, 1993-2015
Figure 2.8 Trend of Current Cigarette Smoking among Adults Aged 18 Years and Over in the US, by Gender and Year, 1991-2015
Figure 2.9 Age Group-wise Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over in the US, by Year, 1965-2014
Figure 2.10 Year-wise Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over in the US, by Age Group, 1965-2014
Figure 2.11 Age Group-wise Prevalence of Current Cigarette Smoking among Females Aged 18 Years and Over in the US, by Year, 1965-2014
Figure 2.12 Year-wise Prevalence of Current Cigarette Smoking among Females aged 18 Years and Over in the US, by Age Group, 1965-2014
Figure 2.13 Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Smoking Status, US, 2013-2015
Figure 2.14 Trend in Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Smoking Status, US, 2013-2015
Figure 2.15 Prevalence (%) of Daily Tobacco Smoking by Gender, US, 2010, 2025 and 2030
Figure 2.16 Prevalence (%) of Current Tobacco Smoking by Gender, US, 2010, 2025 and 2030
Figure 2.17 Trend in Prevalence of Tobacco Smoking among People aged 14 Years and Over, by Smoking Status, Australia, 1991-2015
Figure 2.18 Year-wise Distribution (in %) of Tobacco Smoking Status in Australia in People Aged 14 Years and Above, 1991-2016
Figure 2.19 Trend in Year-wise Distribution of Tobacco Smoking Status in Australia in People Aged 14 Years and Above, 1991-2016 (%)
Figure 2.20 Year-wise Distribution (in %) of Tobacco Smoking Status in Australia in People Aged 12 Years and Above, 2016
Figure 2.21 Trend in Year-wise Distribution of Daily Smokers in Australia, by Age Group, 1991-2016 (%)
Figure 2.22 Trend in Year-wise Distribution of Current Smokers in Australia, by Age Group, 1991-2016 (%)
Figure 2.23 Prevalence (in thousands) of Smoking in Australia, by Age Group, 2014-2015
Figure 2.24 Prevalence (in thousands) of Smoking in Australia, by Age Group and Gender, 2014-2015
Figure 2.25 Distribution (in %) of Tobacco Smoker in Australia, by Age Group and Smoking Status, 2014-2015
Figure 2.26 Five-year Prevalence (%) of Current Tobacco Smoking in Australia, by Gender, 2000-2030
Figure 2.27 Five-year Prevalence(%) of Current Tobacco Smoking in Australia, 2000-2030
Figure 2.28 Trend of Current Tobacco Smoking in Australia, by Age, 2000-2030
Figure 2.29 Five-year Prevalence(%) of Daily Tobacco Smoking in Australia, by Gender, 2000-2030
Figure 2.30 Five-year Prevalence(%) of Daily Tobacco Smoking in Australia, 2000-2030
Figure 2.31 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2006-2016
Figure 2.32 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.33 Trend in Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.34 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.35 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Gender, 2006-2016
Figure 2.36 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.37 Trend in Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.38 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
Figure 2.39 Trend of Prevalence(%) of Current Tobacco Smoking in New Zealand, 1983-2015
Figure 2.40 Five-year Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2000-2030
Figure 2.41 Five-year Prevalence(%) of Daily Tobacco Smoking in New Zealand, 2000-2030
Figure 2.42 Five-year Forecasted Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2000-2030
Figure 2.43 Five-year Prevalence(%) of
Current Tobacco Smoking in New Zealand, 2000-2030
Figure 2.44 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2016
Figure 2.45 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Gender, Italy, 2007-2016
Figure 2.46 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Figure 2.47 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Figure 2.48 Trend in Prevalence (in %) of Smoking in Males Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Figure 2.49 Trend in Prevalence (in %) of Smoking in Females Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
Figure 2.50 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age, Italy, 2007-2016
Figure 2.51 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age, Italy, 2007-2016
Figure 2.52 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
Figure 2.53 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
Figure 2.54 Trend of Current Tobacco Smoking in Italy, by Age, 2000-2030
Figure 2.55 Five-year Prevalence(%) of Daily Tobacco Smoking in Italy, by Gender, 2000-2030
Figure 2.56 Five-year Prevalence (%) of Daily Tobacco Smoking in Italy, 2000-2030
Figure 2.57 Trend in Prevalence (%) of Smoking in People aged 18 Years and Above, by Gender, Germany, 2009-2014/2015
Figure 2.58 Trend in Prevalence(%) of Smoking in People aged 18 Years and Above, Germany, 2009-2014/2015
Figure 2.59 Trend in Prevalence(%) of Smoking in People aged 18 Years and Above, by Age and Gender, Germany, 2009-2014/2015
Figure 2.60 Prevalence(%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
Figure 2.61 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
Figure 2.62 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
Figure 2.63 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
Figure 2.64 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
Figure 2.65 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
Figure 2.66 Trend in Prevalence(%) of Smoking in People aged 15 Years and Above, by Gender and Smoking Status, Germany, 1992-2013
Figure 2.67 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
Figure 2.68 Five-year Prevalence(%) of Current Tobacco Smoking in Germany, 2000-2030
Figure 2.69 Trend of Current Tobacco Smoking in Germany, by Age, 2000-2030
Figure 2.70 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, 2000-2030
Figure 2.71 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, 2000-2030
Figure 2.72 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2014
Figure 2.73 Relative Prevalence (%) of Tobacco Smoking in Population Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2014
Figure 2.74 Number of Tobacco Smokers (in thousands), by Gender and Smoking Status, in Spain, 2011-2012
Figure 2.75 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2011-2012
Figure 2.76 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Gender, in Spain, 1993-2014
Figure 2.77 Trend in Relative Prevalence of Tobacco Smokers (%) in Spain, by Gender, 2011-2012
Figure 2.78 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age Gender, in Spain, 1993-2014
Figure 2.79 Trend in Relative Prevalence of Current Tobacco Smokers (%) in Spain, by Gender, 2011-2012
Figure 2.80 Five-year Prevalence(%) of Current Tobacco Smoking in Spain, by Gender, 2000-2030
Figure 2.81 Five-year Prevalence (%) of Current Tobacco Smoking in Spain, 2000-2030
Figure 2.82 Trend of Current Tobacco Smoking in Spain, by Age, 2000-2030
Figure 2.83 Five-year Prevalence(%) of Daily Tobacco Smoking in Spain, by Gender, 2000-2030
Figure 2.84 Five-year Prevalence(%) of Daily Tobacco Smoking in Spain, 2000-2030
Figure 2.85 Distribution of Smoking Status, in France, 2010 and 2014
Figure 2.86 Trend in Distribution of Smoking Status, in France, 2010 and 2014
Figure 2.87 Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Figure 2.88 Trend in Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Figure 2.89 Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Figure 2.90 Trend in Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
Figure 2.91 Five-year Prevalence(%) of Current Tobacco Smoking in France, by Gender, 2000-2030
Figure 2.92 Five-year Prevalence(%) of Current Tobacco Smoking in France, 2000-2030
Figure 2.93 Trend of Current Tobacco Smoking in France,by Age, 2000-2030
Figure 2.94 Five-year Prevalence(%) of Daily Tobacco Smoking in France, by Gender, 2000-2030
Figure 2.95 Five-year Prevalence (%) of Daily Tobacco Smoking in France, 2000-2030
Figure 2.96 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, in the UK, 2010-2016
Figure 2.97 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2016
Figure 2.98 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2010-2016
Figure 2.99 Trend in Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2010-2016
Figure 2.100 Prevalence(%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.101 Trend in Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.102 Prevalence(%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.103 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.104 Prevalence (%) of Current Tobacco Smoking in Females Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.105 Prevalence(%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.106 Trend in Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.107 Prevalence(%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.108 Prevalence(%) of Daily Tobacco Smoking in Females Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.109 Prevalence(%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
Figure 2.110 Prevalence(%) of Tobacco Smoking in, by Gender and Smoking Status, in the UK, 2010, 2025, and 2030
Figure 2.111 Strategies to Prevent Smoking Initiation in Children and Adolescents
Figure 3.1 Global Smoking Cessation Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 3.2 Global Smoking Cessation Drugs Market Segmentation by Drug Class 2016: Share (%)
Figure 3.3 Global NRT Smoking Cessation Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 3.4 Global Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 3.5 Global Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.6 Trend in Global Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
Figure 3.7 Global Smoking Cessation Drugs Market Segmentation by Drug Class 2027: Share (%)
Figure 3.8 Global Smoking Cessation Drugs Market by Region, 2016: Share (%)
Figure 3.9 Global Smoking Cessation Drugs Market by Region, 2027: Share (%)
Figure 3.10 Smoking Cessation Drugs Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
Figure 3.11 Smoking Cessation Drugs Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
Figure 3.12 Smoking Cessation Drugs Market Forecast 2016-2027, Asia-Pacific: Revenue ($m), AGR (%)
Figure 3.13 Smoking Cessation Drugs Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
Figure 3.14 Global Smoking Cessation Drugs Market by Country, 2016: Share (%)
Figure 3.15 NRT Smoking Cessation Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
Figure 3.16 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
Figure 3.17 North American Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.18 Trend in North American Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
Figure 3.19 NRT Smoking Cessation Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
Figure 3.20 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
Figure 3.21 European Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.22 Trend in European Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
Figure 3.23 NRT Smoking Cessation Market Forecast 2016-2027, APAC: Revenue ($m), AGR (%)
Figure 3.24 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, APAC: Revenue ($m), AGR (%)
Figure 3.25 APAC Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.26 Trend in APAC Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
Figure 3.27 NRT Smoking Cessation Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
Figure 3.28 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
Figure 3.29 RoW Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.30 Trend in RoW Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
Figure 3.31 Trends in Global Smoking Cessation Drugs Market
Figure 6.1 Usage of Any Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016*
Figure 6.2 Usage of Only One Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016*
Figure 6.3 Trend in Number of Prescriptions (in thousands) of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
Figure 6.4 Distribution of Net Ingredient Cost of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
Figure 6.5 Sales of Smoking Cessation Treatments in France, 1998-2016
Figure 7.1 Global Smoking Cessation Market Leaders by Market Share, 2016: Share (%)
Figure 8.1 Global Smoking Cessation Drugs Market Forecast 2017-2027: Revenue ($m), AGR (%)
22nd Century Group, Inc
Actavis (Teva)
AFT Pharmaceuticals
Alphapharm
Apotex
Aveva
Celtic Pharmaceuticals (earlier Xenova Group)
Cerecor Inc
Chefaro Pharma
Chrono Therapeutics
CV Sciences
Douglas Pharmaceuticals
Dr Reddys Labs
Eisai/Arena Pharmaceuticals
Embera NeuroTherapeutics
FDA
Forum Pharmaceuticals Mitsubishi Tanabe Pharma
Geiss, Destin & Dunn (GDD) Inc.
Gelmedic Holding
GSK
GSKSS
Ivax Sub Teva Pharms
Kern Pharma
McNeil (J&J)
Medis Pharma
Merck
Mylan
Nabi Pharmaceuticals (now Aviragen)/GSK
National Institute on Drug Abuse
Novartis
Novartis/Cytos Biotechnology (now Kuros BioSciences)
Office on Smoking and Health
Omega Pharma
Orion Laboratories (Perrigo)
Perrigo
Pfizer
Pharmacia and Upjohn (Pfizer)
Pharmacia Italia
Pierre Fabre
Pinney Associates
Recordati Chimica Industria E Farmaceutica
Reynolds America
Sanofi
Sanofi Aventis
Selecta Biosciences
Tarbis Farma
Teva
The Boots Company
University of Washington
Watson Labs (Teva)
WHO
Wrafton Laboratories (Perrigo)
Download sample pages
Complete the form below to download your free sample pages for Global Smoking Cessation Drugs Market Forecast 2017-2027Download sample pages
Complete the form below to download your free sample pages for Global Smoking Cessation Drugs Market Forecast 2017-2027Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
